An interventional study of Proton Beam Therapy in Abdominal Neuroblastoma, sponsored by The Christie NHS Foundation Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged 3 Months and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by The Christie NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Neuroblastoma with a site in United Kingdom — 8 open to participants now, 15 under way, 4 of them phase 3. Neuroblastoma · United Kingdom.
Among the 52 studies in Neuroblastoma with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 49th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →8 of the 52 studies in Neuroblastoma with a site in United Kingdom are open now. Recruiting first, the newest first:
Renaissance Pharma Ltd. · Sites in United Kingdom, United States, Canada and 4 more countries
Ages 18 mo–18 yrs
Cancer Research UK · Sites in United Kingdom
Ages 18+
University of Birmingham · Sites in United Kingdom, Australia, Austria and 2 more countries
Ages 1+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Australia and 20 more countries
Ages 6 mo–25 yrs
Cancer Research UK · Sites in United Kingdom
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: 3 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 9 · Phase 4 1
First in 1992; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 76 across the 45 interventional studies, 125 across the 1 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 52 have an industry lead sponsor. The 10 most frequent:
The Christie NHS Foundation Trust is the lead sponsor of 100 studies on the registry; 25 are open to participants now.
The Christie NHS Foundation Trust has 1 study filed under Neuroblastoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuroblastoma with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04221035Phase 3Gustave Roussy, Cancer Campus, Grand ParisHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT05990751University College, LondonMulti-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma | 2026-12 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 52 studies in Neuroblastoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Proton Beam Therapy (PBT) and Evaluative Commissioning in Protons (ECIP):
PBT is an advanced radiotherapy technique. There are two National Health Service (NHS) PBT treatment centres in the United Kingdom, in Manchester and London. The NHS is committed to ensuring the best use of this limited resource by investigating which patients will benefit from PBT. ECIP is a programme of studies exploring the role of PBT in different types of cancer funded by NHS England. ECIP studies are not randomised, eligible patients will be offered PBT. Any eligible UK patient can be referred, and accommodation is available for patients who don't live close to a PBT centre. The main benefit of PBT, compared with standard photon radiotherapy, is predicted reduction in radiation dose to surrounding healthy tissues. With photon radiotherapy, some radiation passes beyond the target area, affecting healthy tissues and causing side-effects. With PBT, the radiation dose stops within the target area, causing less damage to surrounding tissues, and limiting side effects.
SUPERMAN:
SUPERMAN is a study within the ECIP programme. It is sometimes not entirely clear whether PBT or photon radiotherapy is better for the treatment of a patient with abdominal neuroblastoma. The aim of SUPERMAN is to choose the best radiotherapy technique and to better understand how to monitor and adapt PBT for these patients.
Introduction:
Neuroblastoma is a rare childhood cancer, occurring in about 100 children in the UK each year. Most arise from nerves in the retroperitoneum - this is an area at the back of the abdomen, behind the stomach and bowel. There are many important structures in the retroperitoneum including the kidneys, adrenal glands, and parts of large blood vessels.
The treatment of neuroblastoma can include surgery, chemotherapy and radiotherapy. Radiotherapy is typically delivered after chemotherapy and surgery, depending on the response to previous treatments. Its aim is to improve local control and overall survival. The dose and schedule of radiotherapy is currently being investigated in a randomised Phase III pan-European trial called SIOPEN-HR-NBL2 (European Society for Paediatic Oncology High-Risk Neuroblastoma 2 trial). It is important to note that any patients involved in SUPERMAN will also be able to participate in any other radiotherapy study, including SIOPEN-HR-NBL2.
How advanced radiotherapy techniques can reduce treatment related side effects:
Typically, patients are diagnosed with neuroblastoma at a very young age, usually under 5 years old. There is a risk of late side-effects following radiation treatment, including secondary cancers. The risk of late-effects, and their severity, may be worse if patients already have health problems, such as problems with kidneys. Kidney problems may be due to the cancer itself or prior treatments. Therefore, particularly for patients most at risk, it is critical to reduce radiotherapy related side effects as much as possible.
In recent years, advances in photon (x-ray) radiotherapy, have improved the accuracy of treatment and reduced high dose radiation to nearby healthy tissues, reducing treatment related side-effects. However, these techniques increase the amount of normal tissue receiving low doses of radiation, and there are concerns about the increased risk of secondary malignancy. This is particularly important in the paediatric population. There will be no increased risk of secondary malignancy from participation in the study.
Proton Beam Therapy (PBT) is a different type of radiotherapy, in which charged particles (protons), rather than photons, are used to deliver treatment. It can potentially reduce the irradiation of nearby healthy tissues even further.
The use of PBT, and the subsequent improved radiation spread in the body, is associated with reduced radiotherapy side effects. The risk of developing radiation induced secondary malignancies for patients with abdominal neuroblastoma has also been estimated to be lower with PBT compared to photon radiotherapy.
The challenges of proton beam therapy and rationale for the study:
Despite the clear potential advantages of PBT, it may not be the best technique for all patients. SUPERMAN aims to address the questions around the decision-making processes for patient selection where the benefits of PBT are uncertain.
PBT treatments are more sensitive to changes in the body. If the body shape changes (e.g. the patient changes weight), or if there are changes inside the body (e.g. as organs move during respiration, or the bowel contains more or less gas than planned for), this could result in the radiotherapy going to the wrong place. Either too much or too little radiotherapy may treat the target region, or too much may be delivered to healthy tissues. The impact of these changes is different for each patient. In SUPERMAN, detailed monitoring of internal motion during treatment will allow us to monitor and estimate its importance for each patient - helping us to tailor treatment accordingly.
These challenges with PBT treatment delivery have led to mixed opinions amongst international experts as to whether there is a benefit with PBT for all neuroblastoma patients. Some groups have retrospectively published their limited experience of using PBT for neuroblastoma, but none have adequately reported on the assessment and management of the relevant changes in the body during treatment. It is therefore unclear from these studies if all neuroblastoma patients can safely be treated with PBT compared to photon delivery methods. A virtual comparative double planning study of PBT versus proton radiotherapy on twenty abdominal neuroblastoma patients has demonstrated that, although most cases will receive a superior treatment plan with PBT, a small proportion would be better served with photon techniques.
Currently policy and aims of the study:
PBT is currently commissioned for all paediatric and teenage young adult patients with abdominal neuroblastoma for whom there is thought to be an advantage. However, knowing who will benefit is not always clear. In some cases, a significant amount of planning needs to be done before a decision can be reached. This leads to uncertainty for everyone, including the patient. We estimate that roughly 10-15% of patients may be better off receiving advanced photon radiotherapy. A decision tool to guide decision making will help clinicians, support patients and improve treatment efficacy and resource use.
Several characteristics are thought to be important when deciding whether PBT or photons would be best for patients. These include the location and size of the tumour before surgery. By studying these factors in detail within SUPERMAN, it is hoped they could be accurately used within a decision tool to decide a patient's best treatment without delay.
Thus, the primary aim of SUPERMAN is to create an easy guide to support the decision-making between PBT and photon techniques, reducing uncertainty and improving treatment efficiency.
SUPERMAN is a multicentre prospective study assessing the feasibility of using an algorithm based on pre-defined clinical characteristics to select patients appropriately with abdominal or abdominal-pelvic neuroblastoma for PBT treatment. This study will also assess delivered dosimetry of PBT plans with adaptive treatment strategies.
Patient identification and referral will follow and leverage the standard pathways and processes for routinely commissioned indications in protons. Patients can potentially be identified at any centre treating this group of patients and referred to the study/PBT centres for consideration for study participation and radiotherapy treatment.
There will be two parts to this study - Technique Selection (Part A) and PBT Treatment Deliverability (Part B). Patients can be enrolled onto either one or both parts of this study.
Part A: Technique Selection
At the time of PBT referral, patients will be stratified into two groups:
Part B: PBT Treatment Deliverability All patients who have PBT technique selected for treatment delivery either on the routine commissioning pathway or Part A should be offered enrolment into Part B of the study. This part of the study will entail detailed monitoring and dosimetric assessment of patients receiving PBT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proton Beam Radiotherapy (PBT) or Intensity Modulated Radiotherapy (IMRT)
Radiation: Proton Beam Therapy
Proton Beam Therapy
Comparison of decision regarding radiotherapy technique selection at three time points of the patient and radiotherapy pathway
Comparison of decision regarding radiotherapy technique selection (PBT vs IMRT) at three time points of the patient and radiotherapy pathway: 1. Selection 1 - Proposed modality at time of referral - Pre-planning 2. Selection 2 - Post planning 3. Selection 3 - Post completion of radiotherapy
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Measure and compare dose to target volume of PBT versus IMRT plans.
For patients who are dual planned, measure and compare dose to target volume, organs at risk and normal tissues of PBT versus IMRT plans (this is a descriptive endpoint).
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Measure and compare dose to organs at risk of PBT versus IMRT plans.
For patients who are dual planned, measure and compare dose to target volume, organs at risk and normal tissues of PBT versus IMRT plans (this is a descriptive endpoint).
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Measure and compare dose to normal tissues of PBT versus IMRT plans.
For patients who are dual planned, measure and compare dose to target volume, organs at risk and normal tissues of PBT versus IMRT plans (this is a descriptive endpoint).
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Number of PBT re-plans and reasons (including delays)
Number of PBT re-plans and reasons (including delays)
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Number of patients requiring PBT to IMRT treatment modality conversions and the reasons for this.
Number of patients requiring PBT to IMRT treatment modality conversions and the reasons for this.
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Evaluation of on-treatment imaging
Monitoring of PBT treatment deliverability, close monitoring of changes in anatomy and variable tissue heterogeneity during treatment is required to ensure that any required adaptive replans can be done within a timely fashion. Patients should have daily kV on board imaging and daily cone beam CT (CBCT) acquired for verification. If changes in anatomy is observed on CBCT, the impact on dosimetry on the current plan will need to be assessed. A traffic light system will be used to evaluate if dosimetric calculation is necessary.
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Evaluation of on-treatment delivery data
The methodology of evaluating on treatment imaging verification and clinical impact of dosimetric assessment during treatment has been described in the outcome measure above. The proportion of CBCTs graded green, amber and red will be recorded. The reasons for amber and red grading will be collected such as bowel gas changes or contour changes along with the attempted strategies applied to mitigate this. The reasons and proportion of patients who required replanning will be recorded and reported. The reasons and proportion of patients initially selected for PBT who required replanning for IMRT treatment (modality conversion) will be recorded and reported. Treatment breaks and delays due to dosimetric concerns, replans or change in modalities will be recorded.
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Comparison of planned versus delivered dose for PBT plans
Compare planned dose versus estimated delivered dose, calculated with review of daily online imaging, for PBT plans.
Time frame: From date of first patient enrolment until the date of the last patient treatment (up to 36 months)
Local control at 2 years
Local control at 2 years as assessed clinically.
Time frame: 2 years from the end of recruitment
Event free survival and overall survival at 2 years
Event free survival and overall survival at 2 years assessed clinically.
Time frame: 2 years from the end of recruitment
Acute toxicity and late toxicity
Acute toxicity measured by clinician assessment and patient reported outcome questionnaire. Late toxicity measured by clinician assessment.
Time frame: 6 weeks after the end of treatment
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2030, 46 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Mar 2025 → Jun 2026, primary completion Mar 2030 → May 2030 and completion Mar 2030 → May 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Christie NHS Foundation Trust →